Abstract:Introduction: Dual Antiretroviral Therapy (DT) has been evaluated as a successful treatment approach in various patient populations, including treatment-naïve and suppressed individuals. However, its effectiveness in experienced patients who become nonadherent due to pill burden, dosing frequency, and/or associated toxicities and develop resistance to it is uncertain. Objectives and Methods: This study aimed to assess the therapeutic efficacy of DT involving dolutegravir (DTG), doravirine (DOR), and darunavir/ cobicistat (DRV/c) or darunavir/ritonavir (DRV/r 600/100 bid) in multi-experienced patients, both suppressed and unsuppressed. For patients experiencing treatment failure, genotypic resistance testing was conducted to evaluate drug efficacy. In cases without treatment failure, regimen selection was based on considerations such as previous toxicities, drug interactions, and clinical history. Results: A total of 72 multi-experienced patients were studied (one with more than one treatment) between 2015 and 2023, mostly men (64%), with ages between 37 and 73 (average 54 ± 9) and a time of infection between 4 and 24 years (median or mean 16 ± 5). The major risk for infection was heterosexual (63%), followed by intravenous drug users (23%). All of them presented with more than one therapeutic drug class resistance, and the most previously used regime was RAL+LPV/R in 18 patients (24%). The most frequent reason for switching was the development of resistance in 30 (41%) of the patients, followed by simplification of the number of doses or tablets in 31 (42%) patients. At the switch, DTG+DRV/c were used in 46 (62%) patients, followed by DTG+DRV/R 600 in 19 (26%) patients. At the end of follow-up, 82% had a viral load of less than 200 cps/mL, 79% less than 100 cps/mL, and 67% had complete viral suppression. Twelve patients were lost for follow-up; seven patients were off medications; and of these, three died with AIDS-defining illnesses. Four additional patients died of non-HIV-related causes, all virally suppressed. Conclusion: The extended evaluation period (6 years) demonstrated that the simplification for dual therapy in patients who were treatment experienced with prior adherence failure with consequent multi-resistant drug patterns is associated with a high degree of efficacy (82%). Many (18%) still dropped out, consistent with findings from other studies. The reduction of pill burden and toxicities are factors that, by promoting a higher adherence rate to treatment, may have contributed to this success.

The Challenge of Adherence to a Complex Antiretroviral Therapy Regimen in an Individual With Multidrug-Resistant HIV

Effective management of multidrug-resistant HIV with lenacapavir and fostemsavir: A case study

Long-acting HIV Fusion Inhibitor Albuvirtide Combined with Ritonavir-Boosted Lopinavir for HIV-1-infected Patients after Failing the First-Line Antiretroviral Therapy: 48-Week Randomized, Controlled, Phase 3 Non-Inferiority TALENT Study

Antiretroviral therapy of a human immunodeficiency virus type 1-infected patient with multiple drug resistance

Achieving virological control in pan-resistant HIV-1 infection: A case series

Hiv Drug Resistance And Its Impact On Antiretroviral Therapy In Chinese Hiv-Infected Patients

Drug Resistance among Adolescents and Young Adults with Virologic Failure of First Line ART and Response to Second Line Treatment.

Long-Term Experience with Dual Therapy in Multi-Experienced Patients. COMBINE Study

Short-Cycle Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Small Cohort of Virally Suppressed People Living with HIV: A Long-Term Follow-Up

A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV

Immunologic, virologic and drug resistance outcomes in an HIV-infected prospective cohort on treatment in South Africa

Impact Of Low-Frequency HIV-1 Drug Resistance Mutations On Antiretroviral Therapy Outcomes

Impact of Human Immunodeficiency Virus Drug Resistance Mutations Detected in Women Prior to Antiretroviral Therapy With Efavirenz + Tenofovir Disoproxil Fumarate + Lamivudine (or Emtricitabine)

Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART

Adherence to antiretroviral therapy among HIV-1 patients from sub-Saharan Africa: a systematic review

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis

HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data

Long-acting drugs and formulations for the treatment and prevention of HIV infection

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)

Influence of the Type of Antiretroviral Treatment on the Time to Reach High Pharmacotherapy Complexity in People Living With HIV